Jordyn Sava is an assistant editor for Targeted Oncology.
Importance of Molecular Imaging in Patients With Prostate CancerDecember 21st 2022
In an interview with Targeted Oncology, Channing J. Paller, MD, discussed the current approaches to radiation therapy, androgen deprivation therapy, and molecular imaging for men with prostate cancer who have biochemical recurrence.
FDA Accepts sBLAs for Enfortumab Vedotin and Pembrolizumab in Locally Advanced or Metastatic UCDecember 20th 2022
For patients with locally advanced or metastatic urothelial cancer, the FDA has accepted for priority review supplemental biologics license applications for enfortumab vedotin-ejfv and pembrolizumab.
Europe Joins US in Approval of Trastuzumab Deruxtecan in HER2+ Gastric CancerDecember 19th 2022
Based on findings from the DESTINY-Gastric01 and -02 trials, the European Commission has approved fam-trastuzumab deruxtecan-nxki monotherapy for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.
Zolbetuximab Combo Meets Efficacy End Points in CLDN18.2+, HER2- Gastric/GEJ CancersDecember 19th 2022
The GLOW trial of zolbetuximab plus capecitabine and oxaliplatin showed statistically significant progression-free and overall survival rates in CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Dostarlimab Extends PFS and Elicits Better Responses vs Pembrolizumab in NSCLCDecember 8th 2022
Frontline treatment with dostarlimab and chemotherapy reduced the risk of disease progression and led to better objective response rates and progression-free survival vs pembrolizumab in patients with metastatic non-squamous non–small cell lung cancer.
ECHELON-1 Trial of Brentuximab Vedotin Improves OS in Classical Hodgkin LymphomaDecember 7th 2022
In an interview with Targeted Oncology, David J. Straus, MD, discussed the newest data of the ECHELON-1 trial which he presented at the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.
Eprenetapopt/Azacitidine After HCT is Positive in TP53-Mutated AML and MDSDecember 2nd 2022
Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic stem-cell transplant induced encouraging relapse-free and overall survival in patients with TP53-mutant acute myeloid leukemia and myelodysplastic syndrome.
Daratumumab With Bortezomib and Dexamethasone Improves Survival in RRMMDecember 2nd 2022
Patients with multiple myeloma administered daratumumab in combination with bortezomib and dexamethasone demonstrated improvements in overall survival compared with those given bortezomib and dexamethasone alone.
UCART19 Shows Promising Safety/Efficacy in Adult Patients With B-Cell ALLNovember 30th 2022
Findings from the phase 1 CALM study evaluating the allogeneic genome-edited anti-CD19 chimeric antigen receptor T-cell product UCART19 show it can be safely used for patients with relapsed or refractory B-cell acute lymphoblastic leukemia.